Bausch Health Companies Inc. reported second quarter 2026 results with consolidated revenues of $2.85 billion, a 13% increase from the prior year period. GAAP net income attributable to Bausch Health was $258 million, or $0.68 per diluted share, compared to $148 million and $0.40 per share in the previous year. Adjusted EBITDA reached $1,075 million, up 28% from the prior year. The company raised its full-year 2026 guidance for revenue to between $10.79 billion and $11.04 billion and adjusted EBITDA to between $4.05 billion and $4.175 billion. Bausch Health operates as a global diversified pharmaceutical and eye health company.

Michael Goettler resigned from the Board of Directors of Bausch Health Companies Inc., effective June 30, 2026, to become President and CEO of Knoa Pharma LLC. The resignation was not due to any disagreement with the Company's operations, policies, or practices. Bausch Health Companies Inc. is a global eye care and pharmaceutical company.